Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder
Key facts
- Who runs it
- Trustees of Dartmouth College
- Where
- Albuquerque, Nashua, Salt Lake City, and Tacoma, United StatesSee the 4 sites
- Trial code
- Status
- Completed
- People taking part
- 149 people enrolled
- Started
- 18 Aug 2022
- Ended
- 5 Feb 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)
- Record updated
- 25 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Site Staff
- 18 years of age and older
- Employed at the clinic as an identified stakeholder role (provider, pharmacist, pharmacy technician, or administrator); Patients
- 18 years of age or older
- A patient of the participating clinic who is receiving or has received MOUD from a provider employed by the clinic
- Exposed to the PrIMO model at the clinic site for at least 14 days
Who cannot take part
- Site Staff
- Unwilling or unable to provide consent
- Are currently in jail, prison, or other overnight facility as required by court of law; or have pending legal action that could prevent participation in study activities; Patients
- Not able to speak English sufficiently to understand study procedures and provide written informed consent
- Unable or unwilling to provide consent or to participate in study procedures
- Are currently in jail, prison, or other overnight facility as required by court of law; or have pending legal action that could prevent participation in study activities
Where in United States
- UNM Truman Health ServicesAlbuquerque, United States
- Harbor Health CareNashua, United States
- Sugar House Health CenterSalt Lake City, United States
- Community Health CareTacoma, United States
About the trial
What the trial wants to find out
This project will provide novel empirical information about how to optimally engage pharmacists and pharmacies as key partners in collaborative integrated care models designed to expand access to evidence-based medication treatment for OUD which may inform a larger experimental design that seeks to evaluate best ways to scale-up this model across the nation. This Phase 1 project seeks to evaluate the feasibility, acceptability, and impact of implementing a pharmacist-integrated model of MOUD into approximately four diverse outpatient clinical sites.
The 2 groups in the trial
- Site StaffOther group
Providers, Pharmacists, Pharmacy Technicians, Administrators to receive survey assessments
Treatment: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)
- PatientsOther group
Subset of patients receiving PrIMO care to receive survey assessments
Treatment: Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Feasibility of Implementing a Pharmacist-Integrated Collaborative Model for Opioid Use Disorder: A Nonrandomized Clinical Trial.Journal of general internal medicine, 2026
- Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations.Addiction science & clinical practice, 2024
- Record updated
- 25 February 2025